Moderna said Tuesday it would enter the final stage of human trials for its COVID-19 vaccine on July 27, to test how well it protects people in the real world.The announcement came as the results from an earlier trial intended to prove the vaccine was safe and triggered antibody production were published.The upcoming Phase 3 trial will recruit 30,000 participants in the US, with half to receive the vaccine at 100 microgram dose levels, and the other half to receive a placebo.Researchers will then track them over two years to determine whether they are protected against infection by the virus.
Or, if they do get infected, whether the vaccine prevents symptoms from developing.If they do get symptoms, the vaccine can still be considered a.